Literature DB >> 11029564

Elimination of procalcitonin and plasma concentrations during continuous veno-venous haemodiafiltration in septic patients.

M Meisner1, E Hüttemann, T Lohs, L Kasakov, K Reinhart.   

Abstract

The elimination of procalcitonin and the course of plasma concentrations during continuous veno-venous haemodiafiltration were measured in patients with sepsis or multiple organ dysfunction syndrome, because these patients are a main target group for the measurement of procalcitonin and often require renal replacement therapy. Procalcitonin was measured in the prefilter plasma and the filtrate at 5 min, 15 min and 1, 2, 4, 6, 12, 24 h after set-up of continuous veno-venous haemodiafiltration. In a prospective study, 19 patients with plasma levels of procalcitonin > 3 ng mL-1 and acute oliguric renal failure treated with continuous veno-venous haemodiafiltration using a polysulphone membrane, were evaluated for the study of clearance. Twenty-one control patients (procalcitonin < 2 ng mL-1) were studied to determine whether filtration itself induced a procalcitonin response. No interventions were required. In patients with low procalcitonin concentrations (procalcitonin < 2 ng mL-1) continuous veno-venous haemodiafiltration did not cause a rise in procalcitonin. In patients with increased procalcitonin plasma concentrations (> 3 ng mL-1), the protein was removed through the polysulphone membrane, with a final clearance of 4 mL min-1 after the initial adsorption period (clearance 0.4-0.9 mL min-1 during the first hour of continuous veno-venous haemodiafiltration). Thus, on the average, approximately 10% of plasma concentrations were measurable in the filtrate ultimately. However, procalcitonin plasma levels were not significantly altered during continuous veno-venous haemodiafiltration (86% of the initial concentration after 24 h). Although procalcitonin is removed from the plasma during continuous veno-venous haemodiafiltration in measurable amounts plasma procalcitonin concentrations did not change significantly during haemodiafiltration. Procalcitonin thus can also be used as a diagnostic parameter in patients undergoing continuous veno-venous haemodiafiltration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11029564     DOI: 10.1046/j.1365-2346.2000.00758.x

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  6 in total

1.  Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients.

Authors:  Raluca Dumea; Dimitrie Siriopol; Simona Hogas; Irina Mititiuc; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2013-08-30       Impact factor: 2.370

2.  Predictive value of procalcitonin for diagnosis of infections in patients with chronic kidney disease: a comparison with traditional inflammatory markers C-reactive protein, white blood cell count, and neutrophil percentage.

Authors:  Yanbei Sun; Lijuan Jiang; Xiaonan Shao
Journal:  Int Urol Nephrol       Date:  2017-09-27       Impact factor: 2.370

3.  Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis.

Authors:  Ashraf A Dahaba; Peter H Rehak; Werner F List
Journal:  Intensive Care Med       Date:  2003-03-22       Impact factor: 17.440

4.  Pre-analytic factors and initial biomarker levels in community-acquired pneumonia patients.

Authors:  Alexander Kutz; Eva Grolimund; Mirjam Christ-Crain; Robert Thomann; Claudine Falconnier; Claus Hoess; Christoph Henzen; Werner Zimmerli; Beat Mueller; Philipp Schuetz
Journal:  BMC Anesthesiol       Date:  2014-11-15       Impact factor: 2.217

Review 5.  Procalcitonin: A promising tool or just another overhyped test?

Authors:  Robin Paudel; Prerna Dogra; Ashley A Montgomery-Yates; Angel Coz Yataco
Journal:  Int J Med Sci       Date:  2020-01-18       Impact factor: 3.738

6.  Usefulness of serum procalcitonin as a diagnostic biomarker of infection in children with chronic kidney disease.

Authors:  Fatina I Fadel; Manal F Elshamaa; Eman A Elghoroury; Ahmed M Badr; Solaf Kamel; Marwa M El-Sonbaty; Mona Raafat; Hebatallh Farouk
Journal:  Arch Med Sci Atheroscler Dis       Date:  2016-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.